The complaint centers on claims that Phreesia misrepresented the stability of its Network Solutions segment. According to the filing, the company touted pharmaceutical marketing commitments as a primary engine for expansion while failing to disclose underlying uncertainties that threatened its financial targets. These public assertions reportedly kept investors in the dark about risks that eventually surfaced, leading to significant shareholder losses.
Phreesia Faces Class Action Over Alleged Misleading Growth Projections
Investors who purchased Phreesia, Inc. stock between May 8, 2025, and March 30, 2026, are being urged to join a securities fraud class action. The Schall Law Firm alleges the company misled the market regarding the reliability of its long-term growth outlook and fiscal 2027 revenue projections.
Brian Schall of the Schall Law Firm is spearheading the effort to represent those affected by the alleged violations of the Securities Exchange Act. Shareholders have until July 13, 2026, to seek lead plaintiff status. Because the class has not yet been certified, individuals who do not take action will remain absent class members without formal legal representation in the current proceedings.
Comments (0)
No comments yet. Be the first!